SC
LGND icon

Steven Cohen’s Ligand Pharmaceuticals LGND Stock Holding History

Steven Cohen’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16,700
Closed -$2.96M – 4045
2025
Q3 		$2.96M Buy
+16,700
New +$2.48M 0.01% 1280
2023
Q2 		– Sell
-81
Closed -$5.98K – 2498
2023
Q1 		$5.98K Buy
+81
New +$5.76K ﹤0.01% 2071
2022
Q3 		– Sell
-4,649
Closed -$259K – 1584
2022
Q2 		$259K Sell
4,649
-132,408
-97% -$7.51M ﹤0.01% 1259
2022
Q1 		$9.62M Buy
137,057
+50,335
+58% +$3.65M 0.04% 523
2021
Q4 		$8.36M Buy
+86,722
New +$8.01M 0.03% 555
2020
Q4 		– Sell
-3,637
Closed -$216K – 1038
2020
Q3 		$216K Buy
+3,637
New +$248K ﹤0.01% 866

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steven Cohen's LGND Position: Q4 2025 in Review

Steven Cohen sold out of Ligand Pharmaceuticals (LGND) in Q4 2025, closing a stake of 16,700 shares — an estimated $2.96M sold.

Steven Cohen first reported a position in LGND in Q3 2020 and held it in 6 quarters. The position peaked at $9.62M in Q1 2022. 350 funds tracked by Wall St. Rank hold LGND as of Q4 2025.

  • Steven Cohen reported no remaining Ligand Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Steven Cohen sold 16,700 Ligand Pharmaceuticals shares in Q4 2025, an estimated $2.96M.
  • Steven Cohen first reported a position in Ligand Pharmaceuticals in Q3 2020 and held it in 6 quarters.
  • Steven Cohen's Ligand Pharmaceuticals position peaked at $9.62M in Q1 2022.
  • 350 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2025.

Based on Point72 Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.